Inclisiran

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 587 publications

Long-Acting RNA Interference Therapies for Cardiovascular Risk Reduction: Current Evidence and Emerging Targets.

Long-Acting RNA Interference Therapies for Cardiovascular Risk Reduction: Current Evidence and Emerging Targets.

Journal: Current cardiology reports

Published: March 06, 2026

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Journal: Expert opinion on pharmacotherapy

Published: March 05, 2026

RNA interference for lipid disorders: is this the future?

RNA interference for lipid disorders: is this the future?

Journal: Current opinion in lipidology

Published: February 28, 2026

Therapeutic innovations in secondary prevention of cardiovascular risk

Therapeutic innovations in secondary prevention of cardiovascular risk

Journal: La Revue du praticien

Published: February 24, 2026

RNA-Based Therapies for Hypercholesterolemia and Coronary Artery Disease.

RNA-Based Therapies for Hypercholesterolemia and Coronary Artery Disease.

Journal: Cureus

Published: February 18, 2026

Imaging-based demonstration of plaque regression and stabilization under inclisiran therapy using non-obstructive general angioscopy.

Imaging-based demonstration of plaque regression and stabilization under inclisiran therapy using non-obstructive general angioscopy.

Journal: European heart journal

Published: February 10, 2026

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Journal: Journal of clinical medicine research

Published: January 30, 2026

Dyslipidemia Management in Stroke Prevention: An individualized approach.

Dyslipidemia Management in Stroke Prevention: An individualized approach.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: January 14, 2026

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Journal: Lipids in health and disease

Published: January 07, 2026

In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.

In hypercholesterolemia, adding inclisiran to individually optimized lipid-lowering therapy improved LDL-C levels at 90 d.

Journal: Annals of internal medicine

Published: January 06, 2026

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

Journal: Microvascular research

Published: December 31, 2025

Dynamics of lipid metabolism parameters following the change of targeted therapy for hypercholesterolemia after acute coronary syndrome

Dynamics of lipid metabolism parameters following the change of targeted therapy for hypercholesterolemia after acute coronary syndrome

Journal: Terapevticheskii arkhiv

Published: December 15, 2025

Showing 1-12 of 587

Last Updated: 04/28/2026